GlobalData on MSN6d
Almirall completes EU regulatory procedure for antifungal Jublia
Almirall has completed the decentralised European regulatory procedure for efinaconazole, a triazole antifungal substance ...
Almirall Announces Completion of Decentralized Regulatory Approval Procedure for Efinaconazole in Europe
Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology announced today the successful ...
The Pharma Letter6d
Almirall’s efinaconazole a step closer to European patients
Almirall has completed the decentralized EU regulatory procedure for efinaconazole (Jublia) for onychomycosis. The final step ...
Morningstar7d
Almirall Announces Completion of Decentralized Regulatory Approval Procedure for Efinaconazole in Europe
With the addition of this treatment, Almirall enhances its European medical dermatology portfolio and reaffirms its commitment to people living with skin infections and dermatologists by providing ...
PharmiWeb7d
Almirall announces completion of decentralized regulatory approval procedure for efinaconazole in Europe
October 15, 2024 – Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology announced today the successful completion of the decentralized regulatory procedure in Europe ...
Business Wire29d
Almirall to Present New Data on Biologics for Psoriasis and Atopic Dermatitis and Celebrates 80 Years of Innovation at the EADV Congress
BARCELONA, Spain--(BUSINESS WIRE)--Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology, today announced its participation in the 33rd Congress of the European ...
Medscape1d
Nemolizumab Reassures in Long-Term Follow-Up Atopic Dermatitis Study
An interim analysis from a long-term open-label extension study has underlined the clinical efficacy and safety of ...
The Bakersfield Californian7d
Almirall Announces Completion of Decentralized Regulatory Approval Procedure for Efinaconazole in Europe
Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology announced today the successful completion of the decentralized regulatory procedure in Europe for ...
DutchNews.NL29d
Almirall to Present New Data on Biologics for Psoriasis and Atopic Dermatitis and Celebrates 80 Years of Innovation at the EADV Congress
New clinical data on Almirall’s biologics portfolio demonstrates further opportunities to positively impact patients and the medical community New data to be presented on tildrakizumab for the ...